ArticleJournal of medical entomology2026
Field evaluation of novel experimental nootkatone-based products for control of Ixodes scapularis and Amblyomma americanum (Acari: Ixodidae).
Article in Journal of medical entomology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A total of eight nature-based products were tested against nymphal blacklegged ticks Ixodes scapularis Say or lone star ticks, Amblyomma americanum (L.) during the summers of 2023 and 2024. Field trials were performed using a micro-plot arena system in a natural field setting. The arena system has previously been used to successfully evaluate products against blacklegged nymphs and was modified for use with lone star nymphs. One of the eight products evaluated in the study, the commercially available BugArmor Zero-Bite, did not exhibit any significant tick-killing activity. The other seven products were nootkatone-based (NootkaSHIELD™) experimental formulations provided by the Swiss company Evolva and still in the product-development process. Of those samples, Evo A (10% nootkatone) and Evo C (10% nootkatone) provided over 94% knockdown control (efficacy within the first two weeks of application) of blacklegged ticks, and 81.2% and 91.0% knockdown control of lone star ticks, respectively. Both formulations also displayed significant residual control (efficacy after 2 weeks post treatment) but results for Evo A (10% nootkatone) varied greatly between 2023 and 2024. Evo B (10% nootkatone) also demonstrated high levels of efficacy, with 78.5% knockdown control and 80.8% residual control. Treatments using the three NootkaSHIELD™ formulations containing 3% nootkatone all resulted in knockdown efficacies below 45%. The results of this study suggest that NootkaSHIELD™ products containing 10% nootkatone are promising candidates for future commercial availability to control ticks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.